Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
ICAAC 2007: Chicago, Illinois; September 17-20, 2007

Key Links:

By Topic:

Search:

  
  • Email Email
  • Glossary Glossary

Interviews With Researchers at ICAAC 2007

ICAAC 2007 Highlights

Cal Cohen, M.D.
  • Calvin J. Cohen, M.D., M.S., Research Director, Community Research Initiative of New England, and Clinical Instructor, Harvard Medical School, Boston, Mass.
    Dr. Cohen gives an overview of research presented on HIV drugs in preclinical development, including the CCR5 inhibitors PRO 140 and vicriviroc, the NNRTI UK-453,061, and an NRTI known as GS-9148.
  • Joseph J. Eron, M.D.
  • Joseph J. Eron, M.D., Associate Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, N.C.
    Dr. Eron reviews highlights of ICAAC, discussing 48-week data of maraviroc (MVC, Selzentry) in the MOTIVATE-1 trial, the head-to-head comparison of darunavir (TMC114, Prezista) + ritonavir (Norvir) to lopinavir/ritonavir (Kaletra) in a trial of treatment-na´ve patients and the results of a French study using interleukin-2 to delay initiation of antiretroviral therapy.
  • Janet Gilmour, M.D., Clinical Associate Professor, University of Calgary Department of Medicine, Calgary, Canada
    Dr. Gilmour gives her view on what she thought were the most interesting presentations at ICAAC 2007. She discusses new research on entry inhibitors and noteworthy basic science presentations.
  • Trevor Hawkins, M.D., Medical Director of Southwest CARE Center, Santa Fe, and Associate Clinical Professor at the University of New Mexico, Albuquerque, N.M.
    Dr. Hawkins provides an update on his view of the most important studies presented at ICAAC, including data presented on CCR5 inhibitors, and the ARTEMIS trial, in which darunavir (TMC114, Prezista) + ritonavir (RTV, Norvir) compared favorably to lopinavir/ritonavir (LPV/r, Kaletra) in treatment-naive patients.
  • Pablo Tebas, M.D.
  • Pablo Tebas, M.D., Director, Adult AIDS Clinical Trials Unit (AACTU) of the University of Pennsylvania and Associate Professor of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa.
    Dr. Tebas discusses the metabolic profiles of the new integrase inhibitors and CCR5 inhibitors; a trial on the use of interleukin-2 to delay antiretroviral therapy initiation, differences between the ARTEMIS and TITAN studies of darunavir (TMC114, Prezista) + ritonavir (RTV, Norvir) and lopinavir/ritonavir (LPV/r, Kaletra. In addition, he provides an update on metabolic complications of HIV/HAART.
  • ICAAC 2007 Study Summaries

  • Juan Berenguer, M.D., Infectious Diseases-HIV Unit, Hospital Gregorio Marañón, Madrid, Spain
    Dr. Berenguer discusses his study comparing two of the most common hepatitis C treatments, pegylated interferon alfa-2a and pegylated interferon alfa-2b.
  • Karen Douville, Executive Director for Project Management, International Partnership for Microbicides, Silver Spring, Md.
    Ms. Douville discusses her poster on the safety of dapivirine, a new vaginal microbicide gel.
  • Joseph J. Eron, M.D.
  • Joseph J. Eron, M.D., Associate Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, N.C.
    Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced patients.
  • Tristan Ferry, M.D.
  • Tristan Ferry, M.D., Service de Maladies Infectieuses, Lyon, France
    Dr. Ferry discusses his poster on incidence and risk factors for non-AIDS-defining, non-HAART-related severe clinical events.
  • Matthew Goetz, M.D., Veteran's Affairs Greater Los Angeles Healthcare System, University of California, Los Angeles School of Medicine, Los Angeles, Calif., and Community Programs for Clinical Research on AIDS
    Dr. Goetz discusses his research on the impact of co-receptor tropism on disease progression in treatment-naive patients.
  • Roy Gulick, M.D., M.P.H.
  • Roy Gulick, M.D., M.P.H., Associate Professor of Medicine, Weill Medical College of Cornell University, and Director, Cornell Clinical Trials Unit, New York City, N.Y.
    Dr. Gulick discusses the results of his two-year study on treatment-experienced patients taking vicriviroc (SCH 417690, SCH-D), a CCR5 inhibitor in development.
  • Jay Lalezari, M.D., Director, Quest Clinical Research, San Francisco, Calif.
    Dr. Lalezari discusses the BOSS study, the first randomized study to examine the use of a needle-free device for the administration of enfuvirtide (T-20, Fuzeon).
  • Claudia Martorell, M.D., M.P.H.
  • Claudia Martorell, M.D., M.P.H., Director of Research, ID Research Institute, Springfield, Mass.
    Dr. Martorell discusses her poster on the use of HLA-B*5701 testing to identify patients at risk for abacavir (ABC, Ziagen) hypersensitivity reaction.
  • Moira McMahon, Johns Hopkins Medical Institute, Baltimore, Md.
    Ms. McMahon discusses her poster on the evolution of drug-resistant HIV in patients taking the hepatitis B drug entecavir.
  • Thomas Nugent, Ph.D., Senior Research Scientist, Gen-Probe Incorporated, San Diego, Calif.
    Dr. Nugent discusses an alternative method for monitoring viral load in patients taking antiretroviral therapy.
  • Lisa Ross, GlaxoSmithKline, Research Triangle Park, N.C.
    Lisa Ross discusses the ALERT study, which compared fosamprenavir (FPV, 908, Lexiva, Telzir) to atazanavir (ATV, Reyataz) + ritonavir (RTV, Norvir) in antiretroviral-naive HIV-infected patients.
  • Michael Silverman, M.D.
  • Michael Silverman, M.D., University of Toronto, Canada
    Dr. Silverman discusses his poster on the declining prevalence of HIV in pregnant women in Zimbabwe -- a 41% drop that may be due to the country's declining economy.
  • Prakash Sista, Ph.D.
  • Prakash Sista, Ph.D., Director, Clinical Virology, VircoLab Inc., Durham, N.C.
    Dr. Sista discusses how the presence of protease inhibitor mutation I50L is associated with HIV drug resistance to atazanavir (ATV, Reyataz) and increased susceptibility to other protease inhibitors in a variety of protease mutational backgrounds.
  • Eric Stawiski, Ph.D., Senior Bioinformatics Scientist, Monogram Biosciences, San Francisco, Calif.
    Dr. Stawiski discusses his poster on how state-of-the-art interpretation algorithms significantly under-report the presence of X4-using virus.
  • Serge Tchamgoue, M.D., Libourne, France
    Dr. Tchamgoue discusses his study on the use of enfuvirtide (T-20, Fuzeon) in antiretroviral-naive patients.
  • Pablo Tebas, M.D.
  • Pablo Tebas, M.D., Director, Adult AIDS Clinical Trials Unit (AACTU) of the University of Pennsylvania and Associate Professor of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa.
    Dr. Tebas discusses why patients interrupting antiretroviral therapy are potentially at a greater risk for cardiovascular disease than if they were on treatment.
  • Eugenia Vispo, Hospital Carlos III, Madrid, Spain
    Eugenia Vispo discusses her poster on the interaction between ribavirin and abacavir (ABC, Ziagen) in HIV/hepatitis C coinfected patients.
  • Ben Young, M.D., Ph.D.
  • Ben Young, M.D., Ph.D., Assistant Clinical Professor of Medicine, University of Colorado and Consultant Physician, Denver ID Consultants, Rose Medical Center, Denver, Colo.
    Dr. Young reviews his presentation, an analysis of kidney function in patients in the HOPS cohort with preexisting kidney disease who received a therapeutic regimen with tenofovir (TDF, Viread).
  • Copyright © 2007 Body Health Resources Corporation. All rights reserved. Podcast disclaimer


      
    • Email Email
    • Glossary Glossary

    Advertisement